Howard Wealth Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$208K Hold
1,318
– – 0.08% 146
2026
Q2
$209K Buy
+1,318
New +$178K 0.08% 150
2022
Q1
– Sell
-2,414
Closed -$270K – 136
2021
Q4
$270K Sell
2,414
-179
-7% -$21.6K 0.14% 109
2021
Q3
$325K Buy
2,593
+44
+2% +$5.67K 0.18% 95
2021
Q2
$345K Buy
2,549
+59
+2% +$7.76K 0.19% 95
2021
Q1
$337K Buy
2,490
+18
+0.7% +$2.7K 0.2% 95
2020
Q4
$348K Buy
2,472
+15
+0.6% +$1.92K 0.22% 91
2020
Q3
$273K Sell
2,457
-74
-3% -$8.3K 0.19% 98
2020
Q2
$283K Buy
+2,531
New +$249K 0.23% 89
2020
Q1
– Sell
-2,406
Closed -$228K – 508
2019
Q4
$228K Hold
2,406
– – 0.19% 92

Other funds holding XBI

Howard Wealth Management's XBI Position: Q3 2026 in Review

Howard Wealth Management held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q3 2026 at 1,318 shares worth $208K. The position accounts for 0.08% of the portfolio, ranked #146.

Howard Wealth Management first reported a position in XBI in Q4 2019 and has held it in 10 quarters since. The position peaked at $348K in Q4 2020. 962 funds tracked by Wall St. Rank hold XBI as of Q3 2026.

  • Howard Wealth Management held 1,318 shares of State Street SPDR S&P Biotech ETF worth $208K as of Q3 2026.
  • Howard Wealth Management left its State Street SPDR S&P Biotech ETF share count unchanged in Q3 2026.
  • State Street SPDR S&P Biotech ETF made up 0.08% of Howard Wealth Management's portfolio in Q3 2026, its #146 holding.
  • Howard Wealth Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2019 and has held it in 10 quarters since.
  • Howard Wealth Management's State Street SPDR S&P Biotech ETF position peaked at $348K in Q4 2020.
  • 962 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2026.

Based on Howard Wealth Management's 13F filing for Q3 2026, filed 28 Oct 2026.